Immunophenotyping, Cytogenetic and Mutational Analysis in newly diagnosed AML patient and corresponding laboratory investigations for therapeutic monitoring and prognosis: Case Report

Abstract

Introduction
Traditionally, AML (Acute Myeloid Leukemia) classification and risk stratification was based on
cytogenetic studies; however, molecular detection of gene mutations has achieved its growing role in classification, risk stratification, and management of AML. Current standard of care combines cytogenetic results with testing for mutations in FLT3, NPM1, CEBPA, and KIT to determine the prognostic subgroup.Case presentation: Here we present a case of AML of 75 years’ male from western Nepal (Asian) who has improved symptoms and laboratory parameters after chemotherapy. Complete recovery from AML has also been reported earlier.
Conclusion:Incorporation of new molecular markers to define prognosis in AML has helped to investigate the newer molecular targeting therapeutic agents.